KNSA - Kiniksa Pharmaceuticals, Ltd.
NASDAQ
->
Healthcare
->
Biotechnology
Hamilton,
Bermuda
Type: Equity
KNSA price evolution
KNSA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $99.27 | $141.08 | $107.95 | |
| Short term investments | $119.49 | $72.47 | $98.42 | |
| Net receivables | $24.89 | $20.45 | $15.99 | $21.27 |
| Inventory | $28.68 | $34.86 | $27.28 | $31.12 |
| Total current assets | $311.3 | $301.02 | $270.59 | $276.3 |
| Long term investments | ||||
| Property, plant & equipment | $11.66 | $12.4 | $13.04 | $12.66 |
| Goodwill & intangible assets | $16.75 | $17 | $17.25 | |
| Total noncurrent assets | $241.41 | $249.08 | $250.03 | |
| Total investments | $119.49 | $72.47 | $98.42 | |
| Total assets | $555.3 | $542.43 | $519.67 | $526.32 |
| Current liabilities | ||||
| Accounts payable | $8.33 | $7.39 | $5.63 | $8.25 |
| Deferred revenue | $11.81 | $11.97 | $12.26 | |
| Short long term debt | $2.08 | $2.28 | $2.25 | |
| Total current liabilities | $95.95 | $84.29 | $64.21 | $63.67 |
| Long term debt | $9.32 | $9.86 | $10.01 | |
| Total noncurrent liabilities | $23.04 | $23.57 | $23.82 | |
| Total debt | $11.4 | $12.14 | $12.26 | |
| Total liabilities | $118.29 | $107.33 | $87.78 | $87.48 |
| Shareholders' equity | ||||
| Retained earnings | -$512.25 | -$499.56 | -$495.65 | -$477.95 |
| Other shareholder equity | -$0.04 | -$0.13 | -$0.05 | $0.01 |
| Total shareholder equity | $435.1 | $431.89 | $438.84 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $107.95 | $122.72 | $122.47 | $114.25 |
| Short term investments | $98.42 | $67.89 | $59.73 | $209.44 |
| Net receivables | $21.27 | $20.32 | $3.98 | |
| Inventory | $31.12 | $21.6 | $3.67 | |
| Total current assets | $276.3 | $243.06 | $196.45 | $333.25 |
| Long term investments | ||||
| Property, plant & equipment | $12.66 | $7.04 | $8.38 | $10.62 |
| Goodwill & intangible assets | $17.25 | $18.25 | $19.25 | |
| Total noncurrent assets | $250.03 | $216.61 | $36.35 | $16.21 |
| Total investments | $98.42 | $67.89 | $59.73 | $209.44 |
| Total assets | $526.32 | $459.67 | $232.8 | $349.46 |
| Current liabilities | ||||
| Accounts payable | $8.25 | $7.9 | $1.87 | $0.5 |
| Deferred revenue | $12.26 | $12 | ||
| Short long term debt | $2.25 | $3.3 | $3.38 | $2.11 |
| Total current liabilities | $63.67 | $47.07 | $44.82 | $31.85 |
| Long term debt | $10.01 | $2.62 | $2.67 | $4.88 |
| Total noncurrent liabilities | $23.82 | $16.46 | $2.94 | $5.68 |
| Total debt | $12.26 | $5.92 | $6.05 | $6.99 |
| Total liabilities | $87.48 | $63.52 | $47.76 | $37.53 |
| Shareholders' equity | ||||
| Retained earnings | -$477.95 | -$492.03 | -$675.4 | -$517.47 |
| Other shareholder equity | $0.01 | $0.04 | -$0.07 | -$0.03 |
| Total shareholder equity | $438.84 | $396.15 | $185.04 | $311.94 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $112.21 | $108.63 | $79.86 | $83.39 |
| Cost of revenue | $12.32 | $10.58 | $9.58 | |
| Gross Profit | $92.11 | $96.31 | $69.28 | $73.81 |
| Operating activities | ||||
| Research & development | $24.02 | $26.33 | $20.05 | |
| Selling, general & administrative | $42.4 | $38.68 | $36.74 | |
| Total operating expenses | $101.76 | $96.43 | $85.82 | $73.73 |
| Operating income | -$0.12 | -$16.54 | $0.08 | |
| Income from continuing operations | ||||
| EBIT | $2.3 | -$14.28 | $2.45 | |
| Income tax expense | $5.49 | $6.21 | $3.43 | -$22.79 |
| Interest expense | $2.46 | |||
| Net income | ||||
| Net income | -$12.69 | -$3.91 | -$17.7 | $25.24 |
| Income (for common shares) | -$3.91 | -$17.7 | $25.24 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $270.26 | $220.18 | $38.54 | |
| Cost of revenue | $33.41 | $22.89 | $9.1 | |
| Gross Profit | $236.85 | $197.28 | $29.44 | |
| Operating activities | ||||
| Research & development | $76.1 | $65.49 | $99.3 | $112.04 |
| Selling, general & administrative | $129.43 | $97.95 | $85.95 | $45.32 |
| Total operating expenses | $262.05 | $187.51 | $186.08 | $157.36 |
| Operating income | -$25.2 | $9.77 | -$156.64 | -$157.36 |
| Income from continuing operations | ||||
| EBIT | -$16.65 | $11.03 | -$156.54 | -$156.23 |
| Income tax expense | -$30.74 | -$172.34 | $1.39 | $5.15 |
| Interest expense | ||||
| Net income | ||||
| Net income | $14.08 | $183.36 | -$157.92 | -$161.38 |
| Income (for common shares) | $14.08 | $183.36 | -$157.92 | -$161.38 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$3.91 | -$17.7 | $25.24 | |
| Operating activities | ||||
| Depreciation | $1.27 | $1.25 | $1.28 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.36 | $7.21 | $7.77 | |
| Total cash flows from operations | $5.17 | $3.99 | $4.33 | |
| Investing activities | ||||
| Capital expenditures | $0.03 | -$0.08 | -$0.06 | |
| Investments | -$46.82 | $25.61 | -$14.84 | |
| Total cash flows from investing | -$27.62 | -$46.8 | $25.52 | -$14.89 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.18 | $3.61 | $0.69 | |
| Net borrowings | ||||
| Total cash flows from financing | $10.12 | -$0.18 | $3.61 | $0.69 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$10.58 | -$41.81 | $33.12 | -$9.87 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $14.08 | $183.36 | -$157.92 | -$161.38 |
| Operating activities | ||||
| Depreciation | $5.39 | $5.44 | $4.99 | $3.81 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $27.15 | $25.12 | $25.17 | $20.88 |
| Total cash flows from operations | $13.3 | $5.81 | -$126.3 | -$136.53 |
| Investing activities | ||||
| Capital expenditures | -$0.13 | -$0.01 | -$0.41 | -$0.28 |
| Investments | -$29.43 | -$8.06 | $149.05 | -$23.16 |
| Total cash flows from investing | -$29.56 | -$8.08 | $128.63 | -$23.44 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.5 | $2.52 | $5.88 | $228.22 |
| Net borrowings | ||||
| Total cash flows from financing | $1.5 | $2.52 | $5.88 | $227.09 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$14.76 | $0.24 | $8.22 | $67.11 |
News
Fundamentals
| Market cap | $2.67B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 72.16M |
| Revenue | $384.10M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$9.07M |
| Revenue Q/Q | 67.37% |
| Revenue Y/Y | 54.41% |
| P/E ratio | -294.51 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 6.95 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.13 |
|---|---|
| ROA | -1.69% |
| ROE | N/A |
| Debt/Equity | 0.20 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.24 |
| Quick ratio | 2.95 |